华润双鹤董事长陆文超荣膺“金牛企业家创新奖”

Core Viewpoint - The 2025 High-Quality Development Forum for Listed Companies and the 27th Golden Bull Award Ceremony highlighted the achievements of companies in the capital market, with Huaren Shuanghe's chairman receiving the "Golden Bull Entrepreneur Innovation Award" for his contributions to innovation and value creation [1][2]. Group 1: Event Overview - The Golden Bull Award, established in 1999, aims to create a credible platform for showcasing listed companies in China's capital market, emphasizing transparency and scientific evaluation [1]. - The award recognizes companies with exemplary governance, performance growth, and positive contributions to shareholders and society [1]. Group 2: Company Innovations and Achievements - During the "14th Five-Year Plan" period, the company adopted a dual-driven approach of "R&D innovation + external development," focusing on developing high-quality drugs that meet clinical needs [2]. - The successful introduction of the innovative drug "Subi One" exemplifies the company's commitment to clinical value and innovation [2]. - The company aims to establish itself as "China's prescription drug number one brand" and is determined to represent state-owned enterprises in innovation and transformation [2]. - In the latest 2025 ranking of China's top 100 chemical drug companies, Huaren Shuanghe advanced to the 13th position, showcasing its competitive edge in a crowded market [2].